<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01720602</url>
  </required_header>
  <id_info>
    <org_study_id>7841</org_study_id>
    <secondary_id>NCI-2012-02004</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT01720602</nct_id>
  </id_info>
  <brief_title>Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy</brief_title>
  <official_title>A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy Part B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer
      receiving hormone therapy. Vorinostat may help hormone therapy work better by making tumor
      cells more sensitive to the drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Estimate the rate of clinical benefit (objective response plus stable disease) for
      patients treated with 28-day cycles of vorinostat (first 5 consecutive days each week for day
      1-21) concurrent with daily aromatase inhibitor (AI) therapy (all 28 days).

      SECONDARY OBJECTIVES:

      I. Assess the safety and tolerability of vorinostat and AI combination therapy in patients
      with metastatic breast cancer.

      II. Assess the change in estrogen receptor (ER) expression, measured as the change in F-18 16
      alpha-fluoroestradiol (FES) standardized uptake value (SUV) using FES positron emission
      tomography (PET) completed per protocol 7184 after two weeks of vorinostat and AI therapy and
      after 8 weeks of therapy.

      III. Assess tumor metabolic response, measured as the change in fludeoxyglucose F 18 (FDG)
      SUV using FDG PET completed per protocol 7184 after two weeks of vorinostat and AI therapy
      and after 8 weeks of therapy.

      IV. Assess the change in hormone levels (estradiol, estrone, follicle-stimulating hormone
      [FSH], sex binding globulin, testosterone, and free testosterone) after 8 weeks of therapy.

      V. Assess the change in ER, progesterone receptor (PR), human epidermal growth factor
      receptor 2 (HER2), androgen receptor (AR), epidermal growth factor receptor (EGFR), vascular
      endothelial growth factor (VEGF) tumor expression after two weeks of vorinostat and AI
      therapy in patients that consent to optional tissue biopsy procedure.

      VI. Assess the time to progression and the overall survival of patients treated with 28-day
      cycles of vorinostat (first 5 consecutive days each week for day 1-21) concurrent with daily
      AI therapy (all 28 days).

      OUTLINE:

      Patients receive vorinostat orally (PO) 5 days a week for 3 weeks. Patients also receive AI
      therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily
      for 4 weeks. Courses repeat every 28 days in the absence of disease progression and
      unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for 2 years,
      then every 6 months until progression, and then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Clinical Benefit of Patients Receiving Vorinostat/AI Combination Therapy According to RECIST</measure>
    <time_frame>8 weeks</time_frame>
    <description>A 90% score (Wilson) confidence interval will be computed for the rate of clinical benefit.
Clinical benefit according to Recist score is defined as: Stable Disease, Partial Remission or Complete Remission. Lack of clinical benefit is defined as Progressive Disease (increase in target lesion size by 20% or more).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Rate According to RECIST</measure>
    <time_frame>8 weeks</time_frame>
    <description>A 90% score (Wilson) confidence interval will be computed for the response rate.
Clinical benefit according to Recist score is defined as: Stable Disease, Partial Remission or Complete Remission. Lack of clinical benefit is defined as Progressive Disease (increase in target lesion size by 20% or more).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Duration of response will be summarized for responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Kaplan-Meier survival curves will be used to describe PFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Kaplan-Meier survival curves will be used to describe overall survival.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Male Breast Cancer</condition>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (vorinostat, AI therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (vorinostat, AI therapy)</arm_group_label>
    <other_name>L-001079038</other_name>
    <other_name>SAHA</other_name>
    <other_name>suberoylanilide hydroxamic acid</other_name>
    <other_name>Zolinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrozole</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (vorinostat, AI therapy)</arm_group_label>
    <other_name>ANAS</other_name>
    <other_name>Arimidex</other_name>
    <other_name>ICI-D1033</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (vorinostat, AI therapy)</arm_group_label>
    <other_name>CGS 20267</other_name>
    <other_name>Femara</other_name>
    <other_name>LTZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exemestane</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (vorinostat, AI therapy)</arm_group_label>
    <other_name>Aromasin</other_name>
    <other_name>FCE-24304</other_name>
    <other_name>PNU 155971</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (vorinostat, AI therapy)</arm_group_label>
    <other_name>FDG-PET</other_name>
    <other_name>PET</other_name>
    <other_name>PET scan</other_name>
    <other_name>tomography, emission computed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>F-18 16 alpha-fluoroestradiol</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (vorinostat, AI therapy)</arm_group_label>
    <other_name>F-18 FES</other_name>
    <other_name>fluorine-18 16 alpha-fluoroestradiol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (vorinostat, AI therapy)</arm_group_label>
    <other_name>18FDG</other_name>
    <other_name>FDG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (vorinostat, AI therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically proven diagnosis of breast cancer

          -  Stage IV disease

          -  Patient has previously derived clinical benefit from endocrine therapy, but is no
             longer deriving benefit to endocrine therapy in the opinion of the treating
             investigator

          -  At least one site of measurable disease, as defined by the modified Response
             Evaluation Criteria in Solid Tumors (RECIST) criteria

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Female patient is post menopausal as defined by one of the following; free from menses
             for &gt;= 2 years, surgically sterilized, FSH and estradiol in post-menopausal range AND
             surgical absence of uterus OR chemotherapy induced amenorrhea lasting &gt; 1 year OR
             currently on ovarian suppression

          -  Female patient of childbearing potential has a negative urine or serum (beta human
             chorionic gonadotropin [B-hCG]) pregnancy test within 14 days prior to receiving the
             first dose of vorinostat

          -  Male patient agrees to use two barrier methods of contraception or abstain from
             intercourse for the duration of the study

          -  Absolute neutrophil count (ANC) &gt;= 1,500/mcL

          -  Platelets &gt;= 50,000/mcL

          -  Hemoglobin &gt;= 9 g/dL

          -  Prothrombin time or international normalized ratio (INR) =&lt; 1.5 x upper limit of
             normal (ULN) unless receiving therapeutic anticoagulation

          -  Partial thromboplastin time (PTT) =&lt; 1.2 times the ULN unless the patient is receiving
             therapeutic anticoagulation

          -  Potassium (K) levels normal limits

          -  Magnesium (Mg) levels normal limits

          -  Calculated creatinine clearance &gt;= 30 mL/min

               -  Creatinine clearance should be calculated per institutional standard

          -  Serum total bilirubin =&lt; 1.5 x ULN

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =&lt; 2.5 x
             ULN

          -  Alkaline phosphatase =&lt; 2.5 x ULN

          -  Patient, or the patient's legal representative, has voluntarily agreed to participate
             by giving written informed consent

          -  Patient has a life expectancy of at least 12 weeks in the opinion of the treating
             investigator

          -  Patient is willing to continue on same AI therapy

          -  Patient agrees to participate in imaging protocol 7184 and is separately consented

        Exclusion Criteria:

          -  Patient has not derived clinical benefit from prior endocrine therapy

          -  Patient is currently participating or has participated in a study with an
             investigational compound or device within 30 days of initial dosing with study drug(s)
             other than the imaging protocol 7184

          -  Patient has received an ER blocking therapy (selective estrogen receptor modulating or
             downregulating selective estrogen receptor modulator [SERM] or selective estrogen
             receptor degrader [SERD] i.e. tamoxifen or fulvestrant) within the past 6 weeks

          -  Patient had prior treatment with an histone deacetylase (HDAC) inhibitor (e.g.,
             romidepsin [Depsipeptide], NSC-630176, MS 275, LAQ-824, belinostat (PXD-101), LBH589,
             MGCD0103, CRA024781, etc); patients who have received compounds with HDAC
             inhibitor-like activity, such as valproic acid, as anti-tumor therapy should not
             enroll in this study; patients who have received such compounds for other indications,
             e.g. valproic acid for epilepsy, may enroll after a 30-day washout period

          -  Patient is on any systemic steroids that have not been stabilized to the equivalent of
             =&lt; 10 mg/day prednisone during the 30 days prior to the start of the study drugs

          -  Patient has known hypersensitivity to the components of study drug or its analogs

          -  Patients with uncontrolled brain metastases

          -  New York Heart Association (NYHA) class III or IV congestive heart failure, myocardial
             infarction within the previous 6 months, QTc &gt; 0.47 seconds, or uncontrolled
             arrhythmia

          -  Type I diabetes mellitus; patients with type II diabetes mellitus will be included as
             long as their glucose can be controlled to under 200 mg/dL

          -  Patient is pregnant or breast feeding, or expecting to conceive or father children
             within the projected duration of the study

          -  Patient with a &quot;currently active&quot; second malignancy, other than non-melanoma skin
             cancer and carcinoma in situ of the cervix, should not be enrolled; patients are not
             considered to have a &quot;currently active&quot; malignancy if they have completed therapy for
             a prior malignancy, are disease free from prior malignancies for &gt; 5 years or are
             considered by their physician to be at less than 30% risk of relapse

          -  Patients with known active viral hepatitis

          -  Patient has a history or current evidence of any condition, therapy, or laboratory
             (lab) abnormality that might confound the results of the study, interfere with the
             patient's participation for the full duration of the study or is not in the best
             interest of the patient to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hannah Linden</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2012</study_first_submitted>
  <study_first_submitted_qc>October 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2012</study_first_posted>
  <results_first_submitted>October 30, 2014</results_first_submitted>
  <results_first_submitted_qc>October 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 6, 2014</results_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Vorinostat, AI Therapy)</title>
          <description>Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
vorinostat: Given PO
anastrozole: Given PO
letrozole: Given PO
exemestane: Given PO
positron emission tomography: Correlative studies
F-18 16 alpha-fluoroestradiol: Correlative studies
fludeoxyglucose F 18: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease on therapy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Vorinostat, AI Therapy)</title>
          <description>Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
vorinostat: Given PO
anastrozole: Given PO
letrozole: Given PO
exemestane: Given PO
positron emission tomography: Correlative studies
F-18 16 alpha-fluoroestradiol: Correlative studies
fludeoxyglucose F 18: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Clinical Benefit of Patients Receiving Vorinostat/AI Combination Therapy According to RECIST</title>
        <description>A 90% score (Wilson) confidence interval will be computed for the rate of clinical benefit.
Clinical benefit according to Recist score is defined as: Stable Disease, Partial Remission or Complete Remission. Lack of clinical benefit is defined as Progressive Disease (increase in target lesion size by 20% or more).</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Vorinostat, AI Therapy)</title>
            <description>Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
vorinostat: Given PO
anastrozole: Given PO
letrozole: Given PO
exemestane: Given PO
positron emission tomography: Correlative studies
F-18 16 alpha-fluoroestradiol: Correlative studies
fludeoxyglucose F 18: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Clinical Benefit of Patients Receiving Vorinostat/AI Combination Therapy According to RECIST</title>
          <description>A 90% score (Wilson) confidence interval will be computed for the rate of clinical benefit.
Clinical benefit according to Recist score is defined as: Stable Disease, Partial Remission or Complete Remission. Lack of clinical benefit is defined as Progressive Disease (increase in target lesion size by 20% or more).</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="35" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Response Rate According to RECIST</title>
        <description>A 90% score (Wilson) confidence interval will be computed for the response rate.
Clinical benefit according to Recist score is defined as: Stable Disease, Partial Remission or Complete Remission. Lack of clinical benefit is defined as Progressive Disease (increase in target lesion size by 20% or more).</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Vorinostat, AI Therapy)</title>
            <description>Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
vorinostat: Given PO
anastrozole: Given PO
letrozole: Given PO
exemestane: Given PO
positron emission tomography: Correlative studies
F-18 16 alpha-fluoroestradiol: Correlative studies
fludeoxyglucose F 18: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate According to RECIST</title>
          <description>A 90% score (Wilson) confidence interval will be computed for the response rate.
Clinical benefit according to Recist score is defined as: Stable Disease, Partial Remission or Complete Remission. Lack of clinical benefit is defined as Progressive Disease (increase in target lesion size by 20% or more).</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="35" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Duration of response will be summarized for responders.</description>
        <time_frame>Up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Vorinostat, AI Therapy)</title>
            <description>Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
vorinostat: Given PO
anastrozole: Given PO
letrozole: Given PO
exemestane: Given PO
positron emission tomography: Correlative studies
F-18 16 alpha-fluoroestradiol: Correlative studies
fludeoxyglucose F 18: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Duration of response will be summarized for responders.</description>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" lower_limit="24.9" upper_limit="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Kaplan-Meier survival curves will be used to describe PFS.</description>
        <time_frame>Up to 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Kaplan-Meier survival curves will be used to describe overall survival.</description>
        <time_frame>Up to 5 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Vorinostat, AI Therapy)</title>
          <description>Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
vorinostat: Given PO
anastrozole: Given PO
letrozole: Given PO
exemestane: Given PO
positron emission tomography: Correlative studies
F-18 16 alpha-fluoroestradiol: Correlative studies
fludeoxyglucose F 18: Correlative studies
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver failure</sub_title>
                <description>Unrelated to the study treatment</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>Unrelated to the study treatment</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>grade 2 (CTCAE v3.0)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <description>grade 3 (CTCAE v3.0)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <description>grade 2 (CTCAE v3.0)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>grade 3 (CTCAE v3.0)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <description>grade 2 (CTCAE v3.0)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Rigors / chills</sub_title>
                <description>grade 2 (CTCAE v3.0)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle cramps</sub_title>
                <description>grade 2 (CTCAE v3.0)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>grade 3 (CTCAE v3.0) The relationship to vorinostat was unclear.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>decrease in glomerular filtration</sub_title>
                <description>grade 1 (CTCAE v3.0)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>creatinine increase</sub_title>
                <description>grade 1-2 (CTCAE v3.0)</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hannah Linden, MD</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-288-6989</phone>
      <email>hmlinden@u.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

